Company intelligence / Profile preview

OncoSynergy

Stamford, Connecticut, United Statesorpha.net ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

OncoSynergy is developing OS2966, a first-in-class anti-CD29 monoclonal antibody that has received FDA Investigational New Drug approval and is advancing to Phase 1 clinical trials in recurrent glioblastoma. The therapeutic targets cancer's "achilles heel" by cutting off multiple biological processes simultaneously, addressing therapeutic resistance which is the number one cause of death in cancer patients[2][5].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

5 assets

OS2966

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on OncoSynergy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoSynergy.

Explore the full profile